Patents by Inventor Celine MONNET
Celine MONNET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814438Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc fragment, wherein the variant exhibits an increased affinity for at least one of the Fc (FcR) fragment receptors selected from among Fc?RIIIa (CD16a), Fc?RIIa (CD32a), and Fc?RIIb (CD32b) receptors, relative to that of the parent polypeptide, characterized in that it comprises at least one mutation chosen from among K290G, Y296W, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262A, V262S, V263T, V264L, V264S, V264T, V266L, V266M, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V, Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S,Type: GrantFiled: July 5, 2017Date of Patent: November 14, 2023Assignee: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventor: Céline Monnet
-
Publication number: 20230265155Abstract: Disclosed is a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: ApplicationFiled: March 31, 2023Publication date: August 24, 2023Inventors: Celine MONNET, Philippe MONDON, Alexandre FONTAYNE, Christophe DE ROMEUF
-
Patent number: 11649271Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: GrantFiled: May 6, 2016Date of Patent: May 16, 2023Assignee: LABORATOIRE FRANÇ-̧AIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Celine Monnet, Philippe Mondon, Alexandre Fontayne, Christophe De Romeuf
-
Publication number: 20210238281Abstract: The present invention relates to an isotype G antibody directed against native myelin oligodendrocytic glycoprotein (MOG), comprising: an Fc fragment exhibiting high sialylation, and an Fab fragment capable of binding to the autoantigen. It also relates to a composition containing such an antibody, and to their uses in therapy.Type: ApplicationFiled: April 19, 2019Publication date: August 5, 2021Inventors: Céline MONNET, Leonardus MARS
-
Publication number: 20210214434Abstract: Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the Fc?RI (CD64), Fc?RIIIa (CD16a) and Fc?RIIa (CD32a) receptors, relative to that of the parent polypeptide, characterised in that it includes: (i) the four mutations 334N, 352S, 378V and 397M; and (ii) at least one mutation chosen from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; the numbering being that of the EU index or the Kabat equivalent.Type: ApplicationFiled: December 14, 2018Publication date: July 15, 2021Inventors: Harry MEADE, Céline MONNET, Philippe MONDON
-
Publication number: 20200087394Abstract: Disclosed is an antibody targeting at least one ligand from an immune checkpoint, having a region Fc that is mutated in relation to that of a parent antibody and has an improved affinity for the receptor FcgRIIIa (CD16a) and/or a higher ADCC activity than the parent antibody.Type: ApplicationFiled: March 19, 2018Publication date: March 19, 2020Inventor: Céline MONNET
-
Publication number: 20190309085Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc fragment, wherein the variant exhibits an increased affinity for at least one of the Fc (FcR) fragment receptors selected from among Fc?RIIIa (CD16a), Fc?RIIa (CD32a), and Fc?RIIb (CD32b) receptors, relative to that of the parent polypeptide, characterized in that it comprises at least one mutation chosen from among K290G, Y296W, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262A, V262S, V263T, V264L, V264S, V264T, V266L, V266M, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V, Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S,Type: ApplicationFiled: July 5, 2017Publication date: October 10, 2019Inventor: Céline Monnet
-
Publication number: 20190292269Abstract: Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an improved half-life with respect to the parent polypeptide, and including at least one mutation of the Fc fragment increasing the binding of Fc to FcRn; and at least one mutation of the Fc fragment increasing the sialylation of Fc.Type: ApplicationFiled: October 27, 2017Publication date: September 26, 2019Inventor: Céline MONNET
-
Publication number: 20190218292Abstract: The present invention relates to an antibody inhibiting at least one immune checkpoint, and having a modified Fc region compared with that of the parent antibody.Type: ApplicationFiled: May 31, 2017Publication date: July 18, 2019Applicant: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOT ECHNOLOGIESInventor: Céline MONNET
-
Publication number: 20180355034Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.Type: ApplicationFiled: July 6, 2016Publication date: December 13, 2018Applicant: Laboratoire Français du Fractionnement et des BiotechnologiesInventors: Philippe Mondon, Céline Monnet-Mars, Alexandre Fontayne, Christophe De Romeuf, Abdessatar Chtourou
-
Publication number: 20180030111Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.Type: ApplicationFiled: May 6, 2016Publication date: February 1, 2018Inventors: Celine MONNET, Philippe MONDON, Alexandre FONTAYNE, Christophe DE ROMEUF
-
Publication number: 20170260254Abstract: The present invention relates to a method for increasing the sialylation of an Fc fragment, including a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat. The present invention also relates to a method for producing a variant of a parent polypeptide including an Fc fragment, the variant having improved sialylation of the Fc fragment relatively to the parent polypeptide, which includes a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat.Type: ApplicationFiled: July 31, 2015Publication date: September 14, 2017Inventors: Celine MONNET, Alexandre FONTAYNE
-
Publication number: 20140378663Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.Type: ApplicationFiled: June 25, 2012Publication date: December 25, 2014Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIESInventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
-
Patent number: 8742074Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: March 19, 2010Date of Patent: June 3, 2014Assignee: Laboratoire Francais du Fractionnement et des BiotechnologiesInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Publication number: 20120009188Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: ApplicationFiled: March 19, 2010Publication date: January 12, 2012Applicant: LFB BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Patent number: RE45992Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: July 23, 2014Date of Patent: May 3, 2016Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
-
Patent number: RE46585Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.Type: GrantFiled: January 12, 2016Date of Patent: October 24, 2017Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars